natgillin/translations-raw huggingface dataset:
In vivo forhindrer ibandronsyre eksperimentelt-induceret knogleødelæggelse forårsaget af ophøret af den gonadale funktion, retinoider, tumorer eller tumorekstrakter. 
In vivo, ibandronic acid prevents experimentally-induced bone destruction caused by cessation of gonadal function, retinoids, tumours or tumour extracts.
Leveren spiller ikke nogen væsentlig rolle ved udskillelsen af ibandronsyre, da det ikke metaboliseres, men udskilles gennem nyrerne, samt ved optagelse i knoglerne. 
The liver has no significant role in the clearance of ibandronic acid since it is not metabolized but is cleared by renal excretion and by uptake into bone.
Inflammation i øjet 
Ocular inflammation
Brug ikke lægemidlet efter den udløbsdato, der står på blisteren og pakningen efter EXP. Udløbsdatoen (Exp) er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the blister and carton after “EXP”.
Efter to år mødte 87,1 % (p<0,001) og 70,5 % af patienterne dette kriterium i armene for henholdsvis 150 mg én gang om måneden og 2,5 mg daglig. 
At two years, 87.1 % (p<0.001) and 70.5 %,of patients met this criterion in the 150 mg monthly and 2.5 mg daily arms respectively.
Brug af anden medicin sammen med Ibandronsyre Teva Fortæl altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig. 
Other medicines and Ibandronic Acid Teva Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
• influenzalignende symptomer, følelse af utilpashed eller smerte 
• flu-like symptoms, feeling generally unwell or in pain
Leveren spiller ikke nogen væsentlig rolle ved udskillelsen af ibandronsyre, som ikke metaboliseres, men udskilles via nyrerne samt optages i knoglerne. 
The liver has no significant role in the clearance of ibandronic acid which is not metabolised but is cleared by renal excretion and by uptake into bone.
I reproduktionsstudier på rotter nedsatte ibandronsyre fertiliteten efter oral indgift. 
In reproductive studies in rats by the oral route, ibandronic acid decreased fertility.
Studier med rotter har påvist reproduktionstoksisitet (se pkt. 
Studies in rats have shown reproductive toxicity (see section 5.3).
Overfølsomh ed†, bronkospasm e†, angioødem †, anafylaktisk reaktion/shoc k 
Hypersensitivi ty†, bronchospasm angioedema†, anaphylactic reaction/shock
Patienten bør have et calcium- og/eller D-vitamintilskud, hvis der ikke indtages nok gennem kosten (se pkt. 
Patients should receive supplemental calcium and / or vitamin D if dietary intake is inadequate (see sections 4.4 and 4.5).
Tabel 3: Resultater fra 3-års frakturstudiet MF 4411 (%, 95 % Konfidensinterval) Placebo (N=974) 
Table 3: Results from 3 years fracture study MF 4411 (%, 95 % CI)
Din læge kan bede dig om at gennemgå et tandeftersyn før behandling med Ibandronsyre Teva. 
Your doctor may ask you to undergo a dental examination before starting treatment with Ibandronic Acid Teva.
Det vides ikke om ibandronsyre udskilles i modermælk. 
It is not known whether ibandronic acid is excreted in human milk.
Den ikke-absorberede del af ibandronsyre udskilles i uændret form via fæces. 
The unabsorbed fraction of ibandronic acid is eliminated unchanged in the faeces.
Overdosering kan dog forårsage øvre gastrointestinale bivirkninger som f.eks. mavebesvær, halsbrand, øsofagitis, gastritis eller mavesår. 
However, oral overdosage may result in upper gastrointestinal events, such as upset stomach, heartburn, oesophagitis, gastritis or ulcer.
• stærke mavesmerter. 
• severe stomach pain.
Primære effektparametre 
Primary efficacy endpoints
Brystsmerter, influenzalignende sygdom, utilpashed, smerter 
Chest pain, influenza-like illness, malaise, pain
Metaboliske interaktioner anses ikke for sandsynlige, da ibandronsyre ikke hæmmer de primære humane CYP-isoenzymer og er vist ikke at inducere CYP-systemet hos rotter (se pkt. 
Metabolic interactions are not considered likely, since ibandronic acid does not inhibit the major human hepatic P450 isoenzymes and has been shown not to induce the hepatic cytochrome P450 system in rats (see section 5.2).
Efter et år (primær analyse) var de mediane, relative ændringer fra baseline -76 % for gruppen, som fik ibandronsyre 150 mg én gang om måneden og -67 % for gruppen, som fik ibandronsyre 2,5 mg daglig. 
After one year (primary analysis) the median relative change from baseline was -76 % for ibandronic acid 150 mg once monthly and -67 % for ibandronic acid 2.5 mg daily.
Filmovertrukket tablet 
Film-coated tablet.
DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE/FORNYELSE AF TILLADELSEN 
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 17 September 2010
Der er ingen relevant nedsættelse af biotilgængeligheden, når ibandronsyre indtages 60 minutter før et måltid. 
There is no meaningful reduction in bioavailability provided ibandronic acid is taken 60 minutes before a meal.
Pædiatrisk population (se pkt 4.2 og pkt. 
Elderly population (see section 4.2)
Derudover hæmmer ibandronsyre ikke de vigtigste humane CYP-isoenzymer og inducerer ikke CYP-systemet hos rotter. 
In addition, ibandronic acid does not inhibit the major human hepatic P450 isoenzymes and does not induce the hepatic cytochrome P450 system in rats.
Knoglenekrose i den ydre øregang er blevet rapporteret ved behandling med bisphosphonat, primært i forbindelse med en langtidsbehandling. 
Osteonecrosis of the external auditory canal has been reported with bisphosphonates, mainly in association with long-term therapy.
Relativ Risiko Reduktion Nye morfometriske vertebrale frakturer 
Relative Risk Reduction New morphometric vertebral fractures
Der er ikke noget, der tyder på en klinisk relevant inter-etnisk forskel i tilstedeværelsen af ibandronsyre mellem asiater og kaukasere. 
There is no evidence for any clinically relevant inter-ethnic differences between Asians and Caucasians in ibandronic acid disposition.
Reduktionen i knoglebrud er vist for brud i rygsøjlen, men ikke for hoftebrud. 
This reduction in fractures was shown for the spine but not for the hip.
Incidensen af øvre gastrointestinale hændelser var den samme hos patienter, som blev behandlet med 150 mg ibandronsyre én gang om måneden, som hos patienter, som blev behandlet med 2,5 mg ibandronsyre daglig. 
Among these patients, the incidence of upper gastrointestinal events in the patients treated with ibandronic acid 150 mg once monthly was similar to that in patients treated with ibandronic acid 2.5 mg daily.
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON
Baseret på erfaringer fra lignende præparater inden for samme klasse vides det dog, at oral overdosering kan forårsage øvre gastrointestinale bivirkninger (som f.eks. mavebesvær, dyspepsi, øsofagitis, gastritis eller mavesår) eller hypocalcæmi. 
However, based on a knowledge of this class of compounds, oral overdose may result in upper gastrointestinal adverse reactions (such as upset stomach, dyspepsia, oesophagitis, gastritis, or ulcer) or hypocalcaemia.
Desuden blev det i en prospektiv planlagt analyse vist, at ibandronsyre 150 mg én gang om måneden var bedre end ibandronsyre 2,5 mg daglig mht. stigning i lumbal BMD efter et år p=0,002 og efter to år p<0,001. 
Furthermore, ibandronic acid 150 mg once monthly was proven superior to ibandronic acid 2.5 mg daily for increases in lumbar spine BMD in a prospectively planned analysis at one year, p=0.002, and at two years, p<0.001.
Patienter med svært nedsat nyrefunktion (CLcr ≤ 30 ml/min), som fik 10 mg peroral ibandronsyre dagligt i 21 dage, havde 2-3 gange højere plasmakoncentrationer end personer med normal nyrefunktion (CLcr > 80 ml/min). 
Subjects with severe renal impairment (CLcr ≤ 30 mL/min) receiving oral administration of 10 mg ibandronic acid daily for 21 days, had 2-3 fold higher plasma concentrations than subjects with normal renal function (CLcr ≥80 mL/min).
Når du har taget Ibandronsyre Teva, skal du vente 1 time, før du spiser dit første måltid og indtager yderligere drikkevarer (se punkt 3. 
After you have taken Ibandronic Acid Teva, please wait for 1 hour before you can have your first food and further drinks.
Hvis du har glemt at tage Ibandronsyre Teva 
If you forget to take Ibandronic Acid Teva
Efter et år var 83,5 % (p=0,006) af patienterne, som fik ibandronsyre 150 mg én gang om måneden og 73,9 % af patienterne, som fik ibandronsyre 2,5 mg daglig, identificeret som respondenter (defineret som et fald ≥ 50 % fra baseline). 
At one year, 83.5 % (p= 0.006) of patients receiving ibandronic acid 150 mg once monthly and 73.9 % of patients receiving ibandronic acid 2.5 mg daily were identified as responders (defined as a decrease ≥50% from baseline).
• svære hudreaktioner 
• severe adverse skin reactions
Da non-steroide antiinflammatoriske lægemidler og bisphosphonater begge er forbundet med gastrointestinal irritation, bør der udvises forsigtighed ved samtidig behandling. 
Since Nonsteroidal Anti-Inflammatory medicinal products and bisphosphonates are both associated with gastrointestinal irritation, caution should be taken during concomitant administration.
Ibandronsyre 150 mg én gang om måneden 
Ibandronic acid 150 mg once monthly
Efter to år var de mediane, relative ændringer -68 % og -62 % i armene for henholdsvis 150 mg én gang om måneden og 2,5 mg daglig. 
At two years the median relative change was -68 % and -62 %, in the 150 mg monthly and 2.5 mg daily arms respectively.
Tabletterne skal synkes hele med et glas vand (180 til 240 ml), mens patienten sidder ned eller står op. Vand med en høj calciumkoncentration må ikke anvendes. 
- Tablets should be swallowed whole with a glass of water (180 to 240 ml) while the patient is sitting or standing in an upright position.
Lør. 
Fri.
Titandioxid (E171) Hypromellose Macrogol 400 
Opadry white YS-1-7003: Titanium dioxide (E 171) Hypromellose Macrogol 400
Patienter med svært nedsat nyrefunktion (CLcr under 30 ml/min) som fik 10 mg oral ibandronsyre dagligt i 21 dage, havde 2-3 gange højere plasmakoncentrationer end personer med normal nyrefunktion og den totale ibandronsyreclearance var 44 ml/min. 
Subjects with severe renal failure (CLcr less than 30 ml/min) receiving daily oral administration of 10 mg ibandronic acid for 21 days, had 2-3 fold higher plasma concentrations than subjects with normal renal function and total clearance of ibandronic acid was 44 ml/min.
Derefter skal du fortsætte med at tage én tablet én gang om måneden på de planlagte dage, som du har markeret i din kalender. 
You should take one tablet the next morning after the day you remember; then, continue taking one tablet once a month on the scheduled days you've marked on your calendar.
Patienten må ikke ligge ned før 1 time efter indtagelse af Ibandronsyre Teva. 
- Patients should not lie down for 1 hour after taking Ibandronic Acid Teva.
Øsofagitis, gastritis, gastroøsofageal reflukssygdom, dyspepsi, diarré, mavesmerter, kvalme 
Oesophagitis, Gastritis, Gastro oesophageal reflux disease, Dyspepsia, Diarrhoea, Abdominal pain, Nausea
Du kan have tidlige tegn på et brud på lårbensknoglen. 
You may have early signs of a possible unusual fracture of the thigh bone.
Der er ikke noget der tyder på en klinisk relevant interetnisk forskel i tilstedeværelsen af ibandronsyre mellem asiater og kaukasere. 
There is no evidence for clinically relevant interethnic differences between Asians and Caucasians in ibandronic acid disposition.
Disse er for eksempel lav BMD, alder, eksistens af tidligere frakturer, familiær tendens til frakturer, høj knogleomsætning og lavt body mass index. 
Independent risk factors, for example, low BMD, age, the existence of previous fractures, a family history of fractures, high bone turnover and low body mass index should be considered in order to identify women at increased risk of osteoporotic fractures.
Invasive tandbehandlinger bør kun udføres efter nøje vurdering under behandling med Ibandronsyre Teva. 
While on treatment, invasive dental procedures should be performed only after careful consideration and be avoided in close proximity to Ibandronic Acid Teva administration.
Produkter indeholdende calcium og andre multivalente kationer (som f.eks. aluminium, magnesium, jern), herunder mælk og føde, vil sandsynligvis påvirke absorptionen af Ibandronsyre Teva. 
Products containing calcium and other multivalent cations (such as aluminium, magnesium, iron), including milk and food, are likely to interfere with absorption of Ibandronic Acid Teva tablets.
Almene symptomer og reaktioner på administration sstedet 
General disorders and administratio n site conditions
Navn og adresse på fremstiller(e) ansvarlig(e) for batchfrigivelse 
Name and address of the manufacturers responsible for batch release
En klinisk relevant reduktion på 50 % i biokemiske markører for knogleresorption blev observeret allerede en måned efter start på behandling med ibandronsyre 2,5 mg. Ved postmenopausal osteoporose ses der ved behandlingsophør en tilbagevenden af forhøjet knogleresportion svarende til det patologiske niveau før behandling. 
A clinically meaningful reduction of 50 % of biochemical markers of bone resorption was observed as early as one month after start of treatment with ibandronic acid 2.5 mg.
Efter to år var 78,7 % (p=0,002) og 65,6 % af patienterne identificeret som respondenter i armene med henholdsvis 150 mg én gang om måneden og 2,5 mg daglig. 
At two years 78.7 % (p=0.002) and 65.6 % of patients were identified as responders in the 150 mg monthly and 2.5 mg daily arms respectively.
Hvis du lider af nyreproblemer, kan din læge vælge at nedsætte dosis til én tablet hver anden dag (i tilfælde af moderat nyresygdom) eller til én tablet om ugen (i tilfælde af alvorlig nyresygdom). 
If you have severe kidney problems, your doctor may reduce your dose to one tablet each week.
Hyppighed af nye morfometriske vertebrale frakturer Relativ Risiko Reduktion af kliniske vertebrale frakturer Hyppighed af kliniske vertebrale frakturer 
Incidence of new morphometric vertebral fractures Relative risk reduction of clinical vertebral fracture Incidence of clinical vertebral fracture
Tag ikke Ibandronsyre Teva 
Do not take Ibandronic Acid Teva
Hvis der blev anvendt et mere stringent kriterium, ved kombination af lumbal BMD og total hofte BMD, var 83,9 % (p<0,001) og 65,7 % af patienterne, som henholdsvis fik ibandronsyre 150 mg én gang om måneden eller ibandronsyre 2,5 mg daglig, respondenter efter et år. 
When a more stringent criterion is considered, which combines both lumbar spine and total hip BMD, 83.9 % (p<0.001) and 65.7 % of patients receiving ibandronic acid 150 mg once monthly or ibandronic acid 2.5 mg daily, respectively, were responders at one year.
• lig ikke ned: Hvis du ikke er oprejst (stående eller siddende), kan noget at medicinen løbe tilbage i spiserøret 
- For the next hour (60 minutes) after you've taken your tablet do not lie down; if you do not stay upright (standing or sitting), some of the medicine could leak back into your oesophagus do not eat anything do not drink anything (except water if you need it) do not take any other medicines
Du kan have tidlige tegn på et brud på lårbensknoglen 
You may have early signs of a possible unusual fracture of the thigh bone
PVC/Aclar/PVC - Aluminiumblistere i papæsker á 1 eller 3 tabletter. 
PVC/Aclar/PVC - Aluminium blisters in cardboard boxes of 1 or 3 tablets.
Efter to år var 93,5 % (p=0,004) og 86,4 % af de patienter, som fik henholdsvis ibandronsyre 150 mg én gang om måneden eller ibandronsyre 2,5 mg daglig, respondenter. 
At two years, 93.5 % (p=0.004) and 86.4 % of patients receiving ibandronic acid 150 mg once monthly or ibandronic acid 2.5 mg daily, respectively, were responders.
Ibandronsyre Teva findes i blistere (PVC/Aclar/PVC - Aluminium) i æsker á 1 eller 3 tabletter. 
Ibandronic Acid Teva comes in blisters (PVC/Aclar/PVC - Aluminium) in cartons of 1 or 3 tablets.
Ibandronsyre 2,5 mg daglig 
Ibandronic acid 2.5 mg daily
Ibandronsyre Teva findes i blistere (PVC/Aclar/PVC - Aluminium) i æsker á 28 eller 84 tabletter. 
Ibandronic Acid Teva comes in blisters (PVC/Aclar/PVC - Aluminium) in cartons of 28 or 84 tablets.
Ibandronsyre Tevas sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt. 
The safety and efficacy of Ibandronic Acid Teva in children and adolescents below the age of 18 years have not been established.
Det skal du vide, før du begynder at tage Ibandronsyre Teva 
What you need to know before you take Ibandronic Acid Teva
Teva Czech Industries s.r.o Ostravska 29/305 
Teva Czech Industries s.r.o Ostravska 29/305, 747 70 Opava-Komarov Czech Republic
PVC/Aclar/PVC - Aluminiumblistere i papæsker a 28 eller 84 tabletter. 
PVC/Aclar/PVC - Aluminium blisters in cardboard boxes of 28 or 84 tablets.
Ibandronsyre Teva filmovertrukne tabletter er hvide, bikonvekse, kapselformede, præget med “I150” på den ene side og ingenting på den anden side. 
The Ibandronic Acid Teva film-coated tablets are white, biconvex, capsule-shaped, engraved “I150” on one side and plain on the other.
Ibandronsyre 150 mg én gang om måneden (N=291) 
Ibandronic acid 150 mg once monthly (N=291)
Ibandronsyre forhindrer in-vivo eksperimentelt fremkaldt knogledestruktion forårsaget af ophørt gonadefunktion, retinoider, tumorer eller tumorekstrakter. 
In vivo, ibandronic acid prevents experimentally induced bone destruction caused by cessation of gonadal function, retinoids, tumours or tumour extracts.
Ikke almindelig (kan forekomme hos færre end 1 ud af 100 behandlede): 
Uncommon (may affect less than 1 in 100 people):
- Hypokalcæmi 
Hypocalcaemia
Artralgi, myalgi, muskuloskeletale smerter, muskelkramper, muskuloskeletal stivhed 
Arthralgia, Myalgia, Musculoskele tal pain, Muscle cramp,
Efter et år (primær analyse) havde 91,3 % (p=0,005) af de patienter, som fik ibandronsyre 150 mg én gang om måneden, en stigning i lumbal BMD over eller lig baseline (BMD respondenter), sammenlignet med 84,0 % af de patienter, som fik ibandronsyre 2,5 mg daglig. 
At one year (primary analysis), 91.3 % (p=0.005) of patients receiving ibandronic acid 150 mg once monthly had a lumbar spine BMD increase above or equal to baseline (BMD responders), compared with 84.0 % of patients receiving ibandronic acid 2.5 mg daily.
Biokemiske markører for knogleomsætning 
Biochemical markers of bone turn-over
Proteinbindingen i humant plasma er ca. 87 % ved terapeutiske stofkoncentrationer. 
Protein binding in human plasma is approximately 87% at therapeutic concentrations, and thus interaction with other medicinal products, due to displacement is unlikely.
• acetylsalicylsyre, non-steroide anti-inflammatoriske lægemidler kaldet NSAIDer, såsom ibuprofen eller naproxen. 
- Acetylsalicylic acid and other non-steroidal anti-inflammatory medicines (NSAIDs) (including ibuprofen, diclofenac sodium and naproxen) may irritate the stomach and intestine.
De patienter, som udvikler knoglenekrose i kæben, bør have en plan for det videre behandlingsforløb, aftalt i samarbejde mellem den behandlende læge og tandlæge, evt. kæbekirurg med speciale i knoglenekrose i kæben. 
The management plan of the patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon with expertise in ONJ.
I et toårs, dobbeltblindt multicenterstudie (BM 16549) var ibandronsyre 150 mg én gang om måneden mindst lige så effektivt som ibandronsyre 2,5 mg daglig til at øge BMD hos postmenopausale kvinder med osteoporose (lumbal BMD T score under -2,5 SD ved baseline). 
Ibandronic acid 150 mg once monthly was shown to be at least as effective as ibandronic acid 2.5 mg daily at increasing BMD in a two year, double-blind, multicentre study (BM 16549) of postmenopausal women with osteoporosis (lumbar spine BMD T score below -2.5 SD at baseline).
Ibandronsyre Teva indeholder: 
What Ibandronic Acid Teva contains
Calciumtilskud, antacida samt visse orale lægemidler indeholdende multivalente kationer Calciumtilskud, antacida samt visse orale lægemidler indeholdende multivalente kationer (som f.eks. aluminium, magnesium, jern) vil sandsynligvis påvirke absorptionen af Ibandronsyre Teva. 
Calcium supplements, antacids and some oral medicinal products containing multivalent cations (such as aluminium, magnesium, iron) are likely to interfere with the absorption of Ibandronic Acid Teva.
En bivirkning kaldet knoglenekrose i kæben (skader på knoglen i kæben) er blevet rapporteret meget sjældent efter markedsføring hos patienter i behandling med Ibandronsyre Teva for osteoporose. 
A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported very rarely in the post-marketing setting in patients receiving Ibandronic Acid Teva for osteoporosis.
Biotilgængeligheden reduceres med ca. 90 %, når ibandronsyre indtages sammen med et almindeligt morgenmåltid i forhold til biotilgængeligheden hos personer i fastetilstand. 
Bioavailability is reduced by about 90% when ibandronic acid is administered with a standard breakfast in comparison with bioavailability seen in fasted subjects.
1 filmovertrukket tablet 3 filmovertrukne tabletter 
3 film-coated tablets
Dosisjustering er ikke påkrævet (se pkt. 
No dose adjustment is required (see section 5.2).
Ibandronsyre 150 mg én gang om måneden (N=320) 
Ibandronic acid 150 mg once monthly (N=320)
En bivirkning kaldet knoglenekrose i kæben (skader på knoglen i kæben) er blevet rapporteret meget sjældent i post-marketing perioden hos patienter ved behandling med Ibandronsyre Teva for kræft relateret forhold. 
A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported very rarely in the post-marketing setting in patients receiving Ibandronic Acid Teva for cancer-related conditions.
Hvis du har taget for mange Ibandronsyre Teva filmovertrukne tabletter Tal straks med en læge eller tag på skadestuen med det samme, hvis du har indtaget for mange tabletter. 
If you take more Ibandronic Acid Teva than you should If you take too many tablets talk to a doctor or go to hospital straight away.
Gastrointestinale bivirkninger 
Gastrointestinal disorders*
Ibandronsyre Teva 50 mg: Lægemidlet må kun udleveres efter begrænset recept (jf. bilag I: Produktresumé; pkt. 
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Ibandronic Acid Teva 50 mg: Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).
Der findes ingen humane data for effekten af ibandronsyre. 
There are no data on the effects of ibandronic acid from humans.
BMD - gennemsnitlig ændring i forhold til baseline - total hofteefter 3 år 
BMD - mean change relative to baseline total hip at year 3
Dette var et sammensat endepunkt, som havde følgende skeletrelaterede hændelser (SREs) inkluderet: - knoglestrålebehandling for behandling af frakturer/truende frakturer 
This was a composite endpoint which had the following skeletal related events (SREs) as sub-components:
Hvide, bikonvekse, kapselformede filmovertrukne tabletter, præget med “50” på den ene side og uden tryk på den anden side. 
White, biconvex, capsule-shaped film-coated tablets, engraved “50” on one side and plain on the other.
Øsofagitis, abdominalsmerter, dyspepsi, kvalme 
Oesophagitis, abdominal pain, dyspepsia, nausea
Fortsat indtagelse af Ibandronsyre Teva 
Continuing to take Ibandronic Acid Teva
For total hofte BMD havde 90,0 % (p<0,001) af de patienter, som fik 150 mg én gang om måneden og 76,7 % af patienterne, som fik ibandronsyre 2,5 mg daglig, stigninger i total hofte BMD over eller lig baseline efter et år. 
For total hip BMD, 90.0 % (p<0.001) of patients receiving ibandronic acid 150 mg once monthly and 76.7 % of patients receiving ibandronic acid 2.5 mg daily had total hip BMD increases above or equal to baseline at one year.
Bivirkningerne ved ibandronsyre hos rotter i reproduktionstoksicitets-studierne var de samme som for øvrige bisphosphonater. 
Adverse effects of ibandronic acid in reproductive toxicity studies in the rat were those observed with bisphosphonates as a class.
Tor. 
Sun.